Latest outcomes of transcatheter left atrial appendage closure devices and direct oral anticoagulant therapy in patients with atrial fibrillation over the past 5 years: a systematic review and meta-analysis

Keiichi Takeda, Yusuke Tsuboko, Kiyotaka Iwasaki*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Left atrial appendage closure (LAAC) are emerging treatment for patients with atrial fibrillation (AF). However, data on the safety, efficacy, and medications for LAAC devices in patients with AF are lacking. We aimed to investigate the incidence of all-cause mortality, stroke, and major bleeding in AF patients with LAAC devices and DOACs. Moreover, we aimed to investigate the incidence rate of device-related thrombus (DRT) and the medications used in the management of AF patients with LAAC devices to gain insights into achieving better outcome. Based on a literature search using PubMed, EMBASE, Cochrane Library, and Web of Science databases between January 2015 and December 2020, eight LAAC device studies that used WATCHMAN and Amulet, and three DOAC studies that used rivaroxaban, with a total of 24,055 AF patients (LAAC devices, n = 2855; DOAC, n = 21,200), were included. A random-effects model was used to incorporate heterogeneity among studies. The pooled incidence of events per person-years were as follows: all-cause mortality, 0.06 (95% confidence interval [CI] 0.02–0.10) for WATCHMAN, 0.04 (95% CI 0.00–0.14) for Amulet, and 0.03 (95% CI 0.01–0.04) for rivaroxaban; stroke; 0.02 (95% CI 0.00–0.04) for WATCHMAN, 0 for Amulet, and 0.01 (95% CI 0.01–0.02) for rivaroxaban; major bleeding, 0.04 (95% CI 0.02–0.06) for WATCHMAN, 0.02 (95% CI 0.00–0.06) for Amulet, and 0.02 (95% CI 0.01–0.03) for rivaroxaban. The incidence rate of DRT was 2.3%, and complications were reported in 9%. The incidence of all-cause mortality, stroke, and major bleeding were similar between LAAC devices and DOACs. The rate of complications was acceptable, and those of DRT were lower than the average incidence reported in previous studies. However, further follow-up is needed. Concomitant anticoagulant and antiplatelet therapies should be further evaluated to find the optimal regimen for AF patients with LAAC devices.

Original languageEnglish
JournalCardiovascular Intervention and Therapeutics
DOIs
Publication statusAccepted/In press - 2022

Keywords

  • Atrial fibrillation (AF)
  • Device-related thrombus (DRT)
  • Direct oral anticoagulants (DOAC)
  • Left atrial appendage closure (LAAC)
  • Meta-analysis

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Latest outcomes of transcatheter left atrial appendage closure devices and direct oral anticoagulant therapy in patients with atrial fibrillation over the past 5 years: a systematic review and meta-analysis'. Together they form a unique fingerprint.

Cite this